GlassScriptPhysician profile
Caleb A Youngblood
NPI 1235366014
$215,491.46
in general payments reported to CMS, 2019-2025
49 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $26K · 2023: $38K · 2024: $46K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $32K · Food and Beverage: $18K · Consulting Fee: $6,470 · Education: $69.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,147.50 |
| Travel and Lodging | $31,744.50 |
| Food and Beverage | $18,468.10 |
| Consulting Fee | $6,470.00 |
| Education | $69.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $144,776.88 | 2021-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $55,342.00 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Theratechnologies INC. | $3,189.66 | 2021-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $2,459.47 | 2021-2025 | Delstrigo, Pifeltro, Gardasil 9 |
| Janssen Scientific Affairs, LLC | $1,160.00 | 2021 | |
| Janssen Biotech, INC. | $1,080.08 | 2021-2023 | Symtuza, Prezcobix |
| Janssen Products, LP | $1,054.96 | 2021-2023 | Symtuza |
| Abbvie INC. | $935.19 | 2021-2025 | |
| Novo Nordisk INC | $588.86 | 2021-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $444.15 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $408.55 | 2021-2025 | |
| Lilly USA, LLC | $361.03 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Teva Pharmaceuticals USA, INC. | $359.36 | 2021-2022 | |
| Antares Pharma, INC. | $323.25 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Napo Pharmaceuticals INC | $309.77 | 2022-2025 | Mytesi |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $262.49 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $231.07 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $213.30 | 2021-2024 | Trintellix, Eohilia |
| Amarin Pharma, INC. | $191.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $144.06 | 2021-2025 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $142.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $138.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.91 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $121.85 | 2023-2025 | Rexulti |
| Amgen INC. | $105.51 | 2021-2025 | Otezla, Repatha, Repatha |
| Halozyme INC | $96.91 | 2023 | |
| Clarus Therapeutics INC. | $93.08 | 2021 | |
| Glaxosmithkline, LLC. | $90.06 | 2021-2025 | Trelegy Ellipta |
| Alk-Abello, INC | $75.77 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Seqirus USA INC | $54.64 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Genentech USA, INC. | $48.96 | 2021 | |
| Verity Pharmaceuticals INC. | $48.56 | 2025 | Tlando, Trelstar |
| Exact Sciences Corporation | $48.26 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $47.98 | 2022-2024 | Quviviq |
| Indivior INC. | $47.11 | 2023-2024 | Sublocade |
| Sanofi Pasteur INC. | $44.91 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.80 | 2025 | Caplyta |
| Tolmar, INC. | $40.08 | 2024-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.65 | 2023-2024 | Xifaxan |
| Corcept Therapeutics | $32.84 | 2025 | Korlym |
| Emd Serono, INC. | $24.81 | 2025 | |
| Abbott Laboratories | $23.47 | 2023 | Freestyle Libre 2 |
| Boston Scientific Corporation | $21.14 | 2024 | Wavewriter Alpha Prime 16 |
| Agios Pharmaceuticals, INC. | $20.07 | 2022 | |
| Hologic Sales and Service, LLC | $18.52 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $17.47 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.12 | 2025 | Azmiro |
| Sanofi-Aventis U.S. LLC | $13.73 | 2021 | |
| Currax Pharmaceuticals LLC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Youngblood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.